Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured CHF 1 million in funding from the UZH Life Sciences Fund (LSF) to advance its lead program for the treatment of Wilson disease.
Wilson disease is a rare genetic disorder that causes toxic copper accumulation in the body, leading to severe neurological and hepatic damage. Current treatments rely on decades-old chelation therapies and often fall short in efficacy and tolerability. metaLead is developing a novel peptide-based therapeutic platform designed to offer a safer, more effective alternative to existing treatments.
The CHF 1 million investment will accelerate the company’s preclinical development toward IND-enabling studies, with a focus on addressing neurological manifestations of the disease.
”This investment marks a significant milestone for metaLead, allowing us to advance our mission to bring better solutions to patients affected by metal-related disorders
Michal ShoshanCEO at metaLead
